This case report describes a 49-year-old woman with stage IV hormone receptor-positive, HER2-negative breast cancer that had spread extensively throughout her skeleton. After being told her disease was inoperable and facing a poor prognosis, she underwent a comprehensive treatment program centered on the metabolic theory of cancer. The protocol combined metabolically supported chemotherapy, a strict ketogenic diet, hyperthermia, hyperbaric oxygen therapy, and a collection of repurposed drugs including metformin, aspirin, doxycycline, mebendazole, ivermectin, and famotidine.

The patient's response was rapid. Severe pain and loss of mobility began improving within weeks, and follow-up PET scans showed substantial reductions in tumor activity. By six months, active bone metastases had largely resolved on imaging, her pain had disappeared, and she had returned to normal daily activities. More than three years after diagnosis, she remained in remission with no evidence of disease progression while continuing a maintenance program built around ketogenic therapy and repurposed medications.

The authors argue that the treatment worked by targeting the metabolic vulnerabilities common to cancer cells. The protocol sought to reduce glucose availability, lower growth signaling, increase metabolic stress, improve oxygen delivery, and simultaneously disrupt multiple pathways involved in tumor survival and spread. While the report describes only a single patient and cannot establish causation, the authors note that this case joins a growing collection of similar reports supporting metabolic therapies for cancer.

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1795402/full